Lii, Theresa R. http://orcid.org/0000-0001-7213-2561
Smith, Ashleigh E.
Flohr, Josephine R. http://orcid.org/0000-0001-9283-8633
Okada, Robin L.
Nyongesa, Cynthia A.
Cianfichi, Lisa J.
Hack, Laura M.
Schatzberg, Alan F. http://orcid.org/0000-0001-9421-8278
Heifets, Boris D. http://orcid.org/0000-0003-1474-0379
Funding for this research was provided by:
Society for Neuroscience in Anesthesia and Critical Care
U.S. Department of Health & Human Services | National Institutes of Health (3T32DA035165-02S1)
Article History
Received: 31 May 2023
Accepted: 14 September 2023
First Online: 19 October 2023
Competing interests
: B.D.H. is on the scientific advisory boards of Osmind and Journey Clinical and is a consultant to Clairvoyant Therapeutics and Vine Ventures. A.F.S. has served as a consultant to Alto Neuroscience, ANeurotech, Compass, Magnus, NeuraWell, Parexal, Sage and Signant. He holds equity in Alto Neuroscience, Corcept, Delpor, Madrigal, Magnus, Seattle Genetics, Titan and Xhale. These interests had no role in the present trial. The other authors declare no competing interests.